Screener
Organon OGN U.S. — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| ($ in millions) | Three Months Ended March 31, 2025 / U.S. | 2025 / Int’l | Total | U.S. | Int’l | Total |
|---|---|---|---|---|---|---|
| Other Non-Opioid Pain, Bone and Dermatology (1) | 3 | 65 | 68 | 4 | 65 | 68 |
| Other | ||||||
| Propecia | 1 | 28 | 30 | 1 | 24 | 26 |
| Emgality | — | 54 | 54 | — | 32 | 32 |
| Proscar | — | 26 | 26 | — | 24 | 24 |
| Other (1) | 3 | 85 | 87 | 3 | 76 | 78 |
| Other (2) | — | 18 | 18 | — | 22 | 22 |
| Revenues | $358 | $1,102 | $1,460 | $412 | $1,101 | $1,513 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's U.S. — revenue?
- Organon (OGN) reported U.S. — revenue of $358M in Q1 2026.
- How has Organon's U.S. — revenue changed year-over-year?
- Organon's U.S. — revenue decreased by 13.1% year-over-year, from $412M to $358M.
- What is the long-term trend for Organon's U.S. — revenue?
- Over 4 years (2021 to 2025), Organon's U.S. — revenue has grown at a 3.8% compound annual growth rate (CAGR), from $1.38B to $1.6B.
- What does U.S. — revenue mean?
- This metric represents the total gross revenue generated by the company's operations within the United States geographic segment. It reflects the market demand for the company's portfolio of prescription therapies, biosimilars, and established brands in this specific region. Tracking this figure helps investors assess the company's competitive position and growth trajectory within the U.S. pharmaceutical market.
Ask your AI about Organon's u.s. — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude